Kidney Cancer Clinical Trial
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
Summary
The purpose of this study is to learn about the effectiveness of the first and later lines of medicines on clinical outcomes in people with mRCC.
The study includes participants who:
are 18 years old or above and have mRCC
took medicines that use the bodies immunity to fight against cancer as their first choice of treatment
took other medicines after taking the above first choice of treatment
This is a study that looks into the data collected through a particular database from selected academic clinical sites participating in this study. The data of interest include:
the length of time between the start of a patient's treatment and the end of treatment
the length of time between the start of treatment and death
physician assessment of a patient's response to treatment
We will compare the experiences of people receiving different combinations of treatments and see if there are any differences in the effectiveness of these medicines.
Eligibility Criteria
Inclusion Criteria:
Diagnosed with mRCC
Age 18 years or over at the time of mRCC diagnosis
Received IO combination treatment in 1L such as receiving ipilimumab + nivolumab or an axitinib-based regimen (ie, axitinib + pembrolizumab or axitinib + avelumab) as 1L
Received subsequent treatments following 1L (e.g., 2L, 3L)
Actively treated at an IMDC clinical center (to avoid incomplete data)
Exclusion Criteria:
- There are no exclusion criteria for this study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
New York New York, 10017, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.